drugset / Trial / NCT07666490
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.
Timeline
- Start
- 2026-06-12
- Primary completion
- 2028-06-13
- Completion
- 2028-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glycopyrronium | Unknown | 12.5 ug | Inhaled |
| Comparator | beclomethasone dipropionate | Other / unclassified | 100 ug | Inhaled |
| Comparator | beclomethasone dipropionate | Other / unclassified | 200 ug | Inhaled |
| Comparator | Formoterol | Other / unclassified | 6 ug | Inhaled |